Ekttitab Holding Company K.S.C Public

DFM:EKTTITAB Stock Report

Market Cap: د.إ72.9m

Ekttitab Holding Company K.S.C Past Earnings Performance

Past criteria checks 0/6

Ekttitab Holding Company K.S.C's earnings have been declining at an average annual rate of -0.5%, while the Capital Markets industry saw earnings growing at 15.9% annually. Revenues have been declining at an average rate of 25.2% per year.

Key information

-0.5%

Earnings growth rate

-0.5%

EPS growth rate

Capital Markets Industry Growth24.8%
Revenue growth rate-25.2%
Return on equity-1.5%
Net Margin931.7%
Last Earnings Update31 Mar 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Ekttitab Holding Company K.S.C makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DFM:EKTTITAB Revenue, expenses and earnings (KWD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 240000
31 Dec 230000
30 Sep 230000
30 Jun 230000
31 Mar 230000
31 Dec 220000
30 Sep 220-220
30 Jun 220-220
31 Mar 220-220
31 Dec 210-220
30 Sep 210-110
30 Jun 210-110
31 Mar 210-110
31 Dec 200-110
30 Sep 200000
30 Jun 200000
31 Mar 200-100
31 Dec 190000
30 Sep 190010
30 Jun 190010
31 Mar 190010
31 Dec 180-110
30 Sep 18-1-110
30 Jun 18-1-210
31 Mar 18-1-210
31 Dec 17-1-110
30 Sep 17-1-110
30 Jun 170-110
31 Mar 170000
31 Dec 16-1-100
30 Sep 16-3-410
30 Jun 16-3-400
31 Mar 16-4-410
31 Dec 15-3-310
30 Sep 15-3-200
30 Jun 15-3-200
31 Mar 15-2-200
31 Dec 14-3-300
30 Sep 14-1-100
30 Jun 14-1-100
31 Mar 14-1-100
31 Dec 13-1-200
30 Sep 13-1-100
30 Jun 13-1-100

Quality Earnings: EKTTITAB is currently unprofitable.

Growing Profit Margin: EKTTITAB is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: EKTTITAB is unprofitable, and losses have increased over the past 5 years at a rate of 0.5% per year.

Accelerating Growth: Unable to compare EKTTITAB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: EKTTITAB is unprofitable, making it difficult to compare its past year earnings growth to the Capital Markets industry (78.3%).


Return on Equity

High ROE: EKTTITAB has a negative Return on Equity (-1.5%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.